Article

What Cannot Be Missed: Important Publications on Electrophysiology in 2019

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image

  • Views: 635

  • Likes: 0

  • Downloads: 9

  • Citations: 1

  • Read time: 3m
Average (ratings)
No ratings
Your rating

Received:

Accepted:

Published online:

DOI:https://doi.org/10.15420/aer.2020.06

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Guidelines and Consensus Statements

1. Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC guidelines for the management of patients with supraventricular tachycardia. The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020;41:655–720. https://doi.org/10.1093/eurheartj/ehz467; PMID: 31504425.

2.Cronin EM, Bogun FM, Maury P, et al. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias Europace 2019;21:1143–4. https://doi.org/10.1093/europace/euz132; PMID: 31075787.

3. Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm 2019;16:e301–72. https://doi.org/10.1016/j.hrthm.2019.05.007; PMID: 31078652.

Important Clinical Trials

1. Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation, the CABANA randomized clinical trial. JAMA 2019;321:1261–74. https://doi.org/10.1001/jama.2019.0693; PMID: 30874766.

2. Katritsis DG, Zografos T, Siontis KC, et al. Endpoints for successful slow pathway catheter ablation in typical and atypical atrioventricular nodal re-entrant tachycardia: a contemporary, multicenter study. JACC Clin Electrophysiol 2019;5:113–9. https://doi.org/10.1016/j.jacep.2018.09.012; PMID: 30678775.

3. Kuck KH, Merkely B, Zahn R, et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. Circ Arrhythm Electrophysiol 2019;12:e007731. https://doi.org/10.1161/CIRCEP.119.007731; PMID: 31760819.

4. Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation 2018;138:1519–29. https://doi.org/10.1161/CIRCULATIONAHA.118.035418; PMID: 29954737.

5. Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA 2019;321:1059–68. https://doi.org/10.1001/jama.2018.15356; PMID: 30874754.

6. Cadrin-Tourigny J, Bosman LP, Nozza A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2019;40:1850–8. https://doi.org/10.1093/eurheartj/ehz103; PMID: 30915475.

7. Barra S, Duehmke R, Providencia R, et al. Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients. Eur Heart J 2019;40:2121–7. https://doi.org/10.1093/eurheartj/ehz238; PMID: 31046090.

8. Andrade JG, Champagne J, Dubuc M, et al. Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial. Circulation 2019;140:1779–88. https://doi.org/10.1007/s40278-019-71404-1; PMID: 31630538.

The Future?

1.Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med 2019;381:1909–17. https://doi.org/10.1056/NEJMoa1901183; PMID: 31722151.

2. Guo Y, Wang H, Zhang H, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. J Am Coll Cardiol 2019;74:2365-2375. https://doi.org/10.1016/j.jacc.2019.08.019; PMID: 31487545.

3. Willems S, Verma A, Betts T, et al. Targeting non-pulmonary vein sources in persistent atrial fibrillation identified by noncontact charge density mapping: the UNCOVER AF trial. Circ Arrhythm Electrophysiol 2019;12:e007233. https://doi.org/10.1161/CIRCEP.119.007233; PMID: 31242746.

4. Reddy VY, Neuzil P, Koruth JS, et al. Pulsed field ablation for pulmonary vein isolation in atrial fibrillation. J Am Coll Cardiol 2019;74:315–26. https://doi.org/10.1016/j.jacc.2019.04.021; PMID: 31085321.

5. Honarbakhsh S, Hunter RJ, Ullah W, et al. Ablation in persistent atrial fibrillation using stochastic trajectory analysis of ranked signals (STAR) mapping method. JACC Clin Electrophysiol 2019;5:817–29. https://doi.org/10.1016/j.jacep.2019.04.007; PMID: 31320010.

6. Grace A, Willems S, Meyer C, et al. High-resolution noncontact charge-density mapping of endocardial activation. JCI Insight 2019;4:e126422. https://doi.org/10.1172/jci.insight.126422; PMID: 30895945.

Next Volume Article